19. Robert Wilson, Feminine Forever (New York: Pocket Books, 1968), 52.
20. Krieger et al., “Hormone Replacement Therapy, Cancer, Controversies, and Women’s Health”; Judith Houck, Hot and Bothered: Women, Medicine, and Menopause in Modern America (Cambridge, MA: Harvard University Press, 2006).
21. Krieger et al., “Hormone Replacement Therapy, Cancer, Controversies, and Women’s Health.”
22. The Writing Group for the PEPI Trial, “Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women: The Postmenopausal Estrogen/ Progestin Interventions (PEPI) Trial.” Journal of the American Medical Association 273, no. 3 (1995): 199–208.
23. Meir J. Stampfer et al., “Postmenopausal Estrogen Therapy and Cardiovascular Disease,” New England Journal of Medicine 325, no. 11 (1991): 756–762.
24. Watkins, The Estrogen Elixir.
25. R. D. Langer, “The Evidence Base for HRT: What Can We Believe?” Climacteric 20, no. 2 (2017): 91–96.
26. Доктор Джоанн Мэнсон, интервью автора.
27. Krieger et al., “Hormone Replacement Therapy, Cancer, Controversies, and Women’s Health.”
28. J. E. Manson et al. for the WHI Investigators, “Menopausal Hormone Therapy and Long-Term All-Cause and Cause-Specifi c Mortality: The Women’s Health Initiative Randomized Trials,” Journal of the American Medical Association 318, no. 10 (2017): 927–938.
29. Lisa Rapaport, “Menopause Hormone Not Linked to Premature Death,” Reuters Health, September 12, 2017.
30. Nanette Santoro et al., “Compounded Bioidentical Hormones in Endocrinology Practice: An Endocrine Society Scientifi c Statement,” Journal of Clinical Endocrinology and Metabolism 101, no. 4 (2016): 1318–1343.
31. Cathr yn Jakobson Ramin, “The Hormone Hoax Thousands Fall For,” More, October 2013, 134–144, 156.
32. North American Menopause Society, “The 2017 Hormone Therapy Position Statement of the North American Menopause Society,” Menopause 24, no. 7 (2017): 728–753.
Джон Хоберман, профессор Техасского университета и автор книги Testosterone Dreams: Rejuvenation, Aphrodisia, Doping (California: University of California Press, 2005), очень помог мне с поиском информации для этой главы. Также я взяла интервью у нескольких экспертов в отрасли, которые занимаются как исследованиями, так и работой с пациентами: доктора Александра Пастушака; доктора Шалендера Бха си на, директора исследовательской программы мужского здоровья Бригхэмского женского госпиталя; доктора Джоэла Финкельштейна, профессора медицины Массачусетского главного госпиталя и Гарвардской школы медицины; доктора Марка Шенберга, профессора урологии Медицинского центра Монтефьоре и Медицинского колледжа им. Альберта Эйнштейна; доктора Элизабет Баррет-Коннор, профессора семейной медицины и здравоохранения Кали форнийского университета в Сан-Диего; доктора Фрэнка Лоу, профессора урологии Медицинского колледжа им. Альберта Эйнштейна; доктора Мартина Майнера, сопредседателя Центра мужского здоровья госпиталя Мири ам, Провиденс, штат Род-Айленд, и доцента семейной меди цины в Университете Брауна; доктора Майкла Вернера, медицинского директора клиники Мейз; доктора Томаса Перлса, директора Новоанглийского исследования столетних и профессора медицины Бостонского университета; доктора Пола Турека, уролога и основателя Turek Clinics; Гершеля Раффа, кандидата наук, профессора медицины, хирургии и физиологии и директора по эндокринным исследованиям Висконсинского медицинского колледжа; Элизабет Уилсон, профессора педиатрии, биохимии и биофизики Университета Северной Каролины; и доктора Джеймса Дюпре, доцента урологии из Мичиганского университета. Исторические данные позаимствованы из книги Arlene Weintraub, Selling the Fountain of Youth: How the Anti-Aging Industry Made a Disease Out of Getting Old – And Made Billions (New York: Basic Books: 2010).
1. Frank A. Beach, “Locks and Beagles,” American Psychologist 24 (1969): 971–989; Benjamin D. Sachs, “In Memoriam: Frank Ambrose Beach,” Psychobiology 16, no. 4 (1988): 312–314.
2. Paul de Kruif, The Male Hormone (New York: Harcourt, Brace, 1945), 107.
3. W. O. Thompson, “Uses and Abuses of the Male Sex Hormone,” Journal of the American Medical Association 132, no. 4 (1946): 185–187; Blakeslee, “Stimulant Found in Pituitary Powder.”
4. Beach, “Locks and Beagles.”
5. Andrea Busnelli et al., “‘Forever Young’—Testosterone Replacement Therapy: A Blockbuster Drug Despite Flabby Evidence and Broken Promises,” Human Reproduction 32, no. 4 (2017): 719–724.
6. Alvaro Morales, “The Long and Tortuous History of the Discovery of Testosterone and Its Clinical Application,” Journal of Sexual Medicine 10, no. 4 (2013): 1178–1183.
7. T. F. Gallagher and Fred C. Koch, “The Testicular Hormone,” Journal of Biological Chemistry 84, no. 2 (1929): 495–500.
8. Claudia Dreifus, “A Conversation with – Anne Fausto-Sterling; Exploring What Makes Us Male or Female,” New York Times, January 2, 2001; Anne Fausto-Sterling, Sexing the Body (New York: Basic Books, 2000).
9. “Science Finds Way to Produce Male Hormone Synthetically,” New York Herald Tribune, September 16, 1935; “Chemist Produces Potent Hormone,” New York Times, September 16, 1935; “Testosterone,” Time, September 23, 1935.
10. “Testosterone,” Time.
11. Sarita Metzger and Arthur L. Burnett, “Impact of Recent FDA Ruling on Testosterone Replacement Therapy (TRT),” Translational Andrology and Urology 5, no. 6 (2016): 921–926. Пример выпуска новостей: Julie Revelant, “10 Warning Signs of Low Testosterone Men Should Never Ignore,” Fox News Health, July 18, 2016, http://www.foxnews.com/health/2016/07/18/10-warning-signs-low-testosterone-men-should-never-ignore.html.
12. August Werner, “The Male Climacteric,” Journal of the American Medical Association 112, no. 15 (1939): 1441.
13. Доктор Джон Морли, интервью автора.
14. Stephen R. Braun, “Promoting ‘Low T’: A Medical Writer’s Perspective,” JAMA Internal Medicine 173, no. 15 (2013): 1458–1460.
15. Стивен Браун, интервью автора.
16. C. Lee Ventola, “Direct-to-Consumer Pharmaceutical Advertising: Therapeutic or Toxic?” Pharmacy and Therapeutics 36, no. 10 (2011): 669–684; Samantha Huo et al., “Treatment of Men for ‘Low Testosterone’: A Systematic Review,” PLOS ONE 11, no. 9 (2016): e0162480.
17. Hoberman, Testosterone Dreams, 120.
18. Metzger and Burnett, “Impact of Recent FDA Ruling.”
19. Shalender Bhasin et al., “Testosterone Therapy in Adult Men with Androgen Defi ciency Syndromes: An Endocrine Society Clinical Practice Guidline,” Journal of Clinical Endocrinology and Metabolism 95, no. 6 (2010): 2536–2559; Frederick Wu et al., “Identifi cation of Late-Onset Hypogonadism in Middle-Aged and Elderly Men,” New England Journal of Medicine 363, no. 2 (2010): 123–135; G. R. Dohle et al., “Guidelines on Male Hypogonadism,” European Association of Urology, 2014, http://uroweb.org/wp-content/uploads/18-Male-Hypogonadism_LR1.pdf.
20. Joseph Scott Gabrielsen et al., “Trends in Testosterone Prescription and Public Health Concerns,” Urologic Clinics of North America 43, no. 2 (2016): 261–271; Katherine Margo and Robert Winn, “Testosterone Treatments: Why, When, and How?” American Family Physician 73, no. 9 (2006): 1591–1598.
21. L. M. Schwartz and S. Woloshin, “Low ‘T’ as in ‘Template’: How to Sell Disease,” JAMA Internal Medicine 173, no. 15 (2013): 1460–1462.
22. W. J. Bremner et al., “Loss of Circadian Rhythmicity in Blood Testosterone Levels with Aging in Normal Men,” Journal of Clinical Endocrinology and Metabolism 56, no. 6 (1983): 1278–1281.
23. Fred Sattler et al., “Testosterone and Growth Hormone Improve Body Composition and Muscle Performance in Older Men,” Journal of Clinical Endocrinology and Metabolism 94, no. 6 (2009): 1991–2001.
24. Доктор Александр Пастушак, интервью автора.
25. A. M. Matsumoto, “Effects of Chronic Testosterone Administration in Normal Men: Safety and Effi cacy of High Dosage Testosterone and Parallel Dose-Dependent Suppression of Luteinizing Hormone, Follicle-Stimulating Hormone, and Sperm Production,” Journal of Clinical Endocrinology and Metabolism 70, no. 1 (1990): 282–287.
26. L. Frederiksen et al., “Testosterone Therapy Decreases Subcutaneous Fat and Adiponectin in Aging Men,” European Journal of Endocrinology 166 (2012): 469–476.
27. Shehzad Basaria et al., “Adverse Events Associated with Testosterone Administration,” New England Journal of Medicine 363, no. 2 (2010): 109–122; S. Basaria et al., “Effects of Testosterone Administration for 3 Years on Subclinical Atherosclerosis Progression in Older Men with Low or Low-Normal Testosterone Levels: A Randomized Clinical Trial,” Journal of the American Medical Association 314, no. 6 (2015): 570–581.
28. P. J. Snyder et al., “Effects of Testosterone Treatment in Older Men,” New England Journal of Medicine 374, no. 7 (2016): 611–624.
29. Felicitas Buena et al., “Sexual Function Does Not Change when Serum Testosterone Levels Are Pharmacologically Varied within the Normal Male Range,” Fertility and Sterility 59, no. 5 (1993): 1118–1123; Christina Wang et al., “Transdermal Testosterone Gel Improves Sexual Function, Mood, Muscle Strength, and Body Composition Parameters in Hypogonadal Men,” Journal of Clinical Endocrinology and Metabolism 85, no. 8 (2000): 2839–2853.
30. Доктор Шалендер Бхасин, интервью автора.
31. Darius Paduch et al., “Testosterone Replacement in Androgen-Defi cient Men With Ejaculatory Dysfunction: A Randomized Controlled Trial,”